Influenza Pipeline — VivoSeq

Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study of the Safety and Efficacy of BPL-1357 Against H1N1 Influenza Virus Challenge

Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT07215858·129 enrolled

A Phase 1, Dose-escalation, Blinded Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children (9 to <18 Years of Age)

Recruiting· Moderna logo

Moderna·Phase 1·NCT07870330·96 enrolled

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of CD388, a Novel Long-Acting Antiviral Conjugate, for the Prevention of Influenza in Adults and Adolescents at Higher Risk of Developing Influenza Complications

Recruiting·CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)·Phase 3·NCT07159763·10,000 enrolled

A Phase IIIb Multicenter, Single-arm, Open-label Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Patients With Influenza and Transmission of Influenza to Household Contacts

Recruiting· Roche logo

Roche·Phase 3·NCT06094010·1,100 enrolled

A Randomized, Double Blind, Placebo Controlled Trial of Intravenous N-acetylcysteine and Oseltamivir Versus Intravenous 5% Dextrose and Oseltamivir in Adults Hospitalized With Influenza Complicated by Lower Respiratory Tract Infection.

Recruiting·CChinese University of Hong Kong·Phase 3·NCT03900988·160 enrolled

A Double-Blinded, Randomized Influenza Virus Challenge Trial of Recombinant Influenza RG-A/Arkansas/08/2020 (pH1N1) in Healthy Adults to Assess Safety and Optimal Infectious Dose

Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT07110532·90 enrolled

Mucosal and Systemic Immunity Correlates of Protection Against Influenza in Young Children (MUSIC-Flu)

Recruiting·National Institute for Communicable Diseases, South Africa·N/A·NCT07861854·150 enrolled

Evaluating the Clinical Outcomes of Abbott ID NOW Point-of-Care Testing for Respiratory Illnesses in Long-Term Care Facility Residents in Taiwan: Cluster-Randomized Controlled Trial

Recruiting·CChina Medical University Hospital·Preclinical·NCT07846423·1,080 enrolled

A Phase 1/2, Parallel, Observer-blind Study to Assess the Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Years of Age and Above.

Recruiting· Sanofi logo

Sanofi·Preclinical·NCT07779408·640 enrolled

Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies

Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT04772170·1,000 enrolled

Dime La VerDAD: Verify, Debunk, and Disseminate

Recruiting·UUniversity of Chicago·Preclinical·NCT06417762·1,400 enrolled

Respiratory Virus Sampling and Repository

Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT05266222·20,000 enrolled

Relative Vaccine Effectiveness of Adjuvanted Inactivated Influenza Vaccine (aIIV) vs High-Dose Inactivated Influenza Vaccine (HD-IIV) for Prevention of Lab-Confirmed Influenza Among Adults ≥65 Years of Age in the United States

Recruiting·—·N/A·NCT06029933·1,500,000 enrolled

Surveillance, Assessment and Detection of Influenza-Associated Respiratory Infections in HIV-Positive and HIV-Negative Individuals in Lusaka, Zambia

Recruiting·CCentre for Infectious Disease Research in Zambia·N/A·NCT07030075·594 enrolled

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of Onradivir Tablets in Participants Aged 12 to 17 Years With Uncomplicated Influenza A.

Recruiting·RRuijin Hospital·Phase 3·NCT07229547·150 enrolled

Influenza

Pipeline Metrics

Competitive Landscape

Top Companies

Programs by Phase

Modality Breakdown

Trial Status

Trial Activity